Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation

Blood

Volumn 97, Issue 5, 2001, Pages 1232-1240

  Cwynarski, Kate ^b   Ainsworth, Jenni ^b   Cobbold, Mark ^b   Wagner, Simon ^b   Mahendra, Prem ^b   Apperley, Jane ^b   Goldman, John ^b   Craddock, Charles ^b   Moss, Paul A H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUCONAZOLE; FLUORESCEIN ISOTHIOCYANATE; FOSCARNET; GANCICLOVIR; HLA ANTIGEN; PREDNISOLONE; STEROID;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGRAFT; ARTICLE; CANCER RADIOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MALE; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; VIRUS REACTIVATION;

EID: 0035282725     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.5.1232     Document Type: Article

References (41)

1. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation
2. Risk factors for cytomegalovirus infection after human marrow transplantation
3. Cytomegalovirus pneumonia after bone marrow transplantation: Risk factors and response to therapy
4. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
5. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial
6. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
7. A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation
8. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis
9. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: Comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture
10. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection
11. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
12. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones
13. Phenotypic analysis of antigen-specific T lymphocytes
14. Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection
15. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
16. - T cells specific for EBV in healthy virus carriers
17. Cytotoxic T lymphocyte precursor frequency analyses in bone marrow transplantation with volunteer unrelated donors: Value in donor selection
18. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia
19. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors
20. Comparison of plasma PCR and bronchoalveolar lavage fluid culture for detection of cytomegalovirus infection in adult bone marrow transplant recipients
21. CD45: An emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development
22. + memory T cells re-acquire CD45RA without losing CD45RO
23. + T cells comprise both naive and memory cells
24. + T cells specific for EBV in healthy virus carriers
25. +) T-helper cells after human allogeneic bone marrow transplantation
26. + T lymphocytes in healthy seropositive donors
27. + cytotoxic T-lymphocytes in liver transplant patients
28. + T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants
29. The effect of cytomegalovirus infection on T lymphocytes after allogeneic bone marrow transplantation
30. Effect of cytomegalovirus infection on T-lymphocytes after lymphocyte-depleted bone marrow transplantation
31. + T cells after allogeneic BMT is related with a low incidence of relapse and with cytomegalovirus infection
32. Evidence for transfer of cellular and humoral immunity to cytomegalovirus from donor to recipient in allogeneic bone marrow transplantation
33. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections
34. Cytomegalovirus infection after bone marrow transplantation: An association with acute graft-v-host disease
35. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients
36. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation
37. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: Relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease
38. + T cells
39. Bone marrow transplantation from unrelated donors in chronic myelogenous leukemia
40. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease
41. Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation